Bioanalytical and CMC testing services provider Alliance Pharma will open a bioanalytical laboratory in Brisbane Australia, the company has announced.
Alliance expects the facility to be fully operational by November 2022, where it enable the company to transfer methods and maintain continuous project management across its global bioanalytical sites in the US and Europe.
The new 20,000 square foot purpose-built facility will contain an expansive state-of-the-art lab, providing small and large molecule bioanalytical services for the Brisbane region.
“With the speed to start Phase I studies, quality of clinical sites and a favorable Australian R&D tax credit, Australia is an optimal market for early phase clinical research,” said Alliance CCO Vito Saccente. “Alliance will not only be able to provide services critical to this market, but also when these compounds move to Phase II, we are well-positioned to transfer methods without losing critical knowledge and can continue to support the progression of clinical development for our clients.”